Nicardipine hydrochloride sustained release pellets and preparation method thereof
A technology of nicardipine hydrochloride and nicardipine hydrochloride, which is applied in the direction of microcapsules, bulk delivery, and cardiovascular system diseases, and can solve the problems of packaging, transportation, and storage inconvenience, low drug release stability, and large gastrointestinal irritation and other issues, to achieve the effect of improving bioavailability, small individual differences, and easy absorption
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0029] A nicardipine hydrochloride sustained-release pellet, comprising drug-containing pellets and a coating layer, characterized in that: the coating layer wraps the drug-containing pellets, and the drug-containing pellets include: 10 mg of nicardipine hydrochloride , 70mg blank ball core, 110-150mg filler, 18-68mg lubricant, 2-10mg binder, the coating layer includes: 29-145mg Eudragit NE30D, 4-44mg talcum powder.
[0030] The optimal mass ratio of raw materials in the drug-containing pellets is: 10 mg nicardipine hydrochloride, 70 mg blank pellet core, 140 mg filler, 35 mg lubricant, and 5 mg binder.
[0031] The optimal mass ratio of raw materials in the coating layer is: 59mg Eudragit NE30D, 13mg talcum powder.
[0032] The filler is microcrystalline cellulose.
[0033] Described lubricant is talcum powder.
[0034] The binder is hypromellose.
[0035] The coating layer also includes traces of sodium lauryl sulfate or polyethylene glycol.
Embodiment 2
[0037] A preparation method of nicardipine hydrochloride sustained-release pellets, comprising the following steps:
[0038] Step 1: material preparation: according to the above mass ratio, nicardipine hydrochloride is pulverized with a pulverizer, and passed through a 100-mesh sieve;
[0039] Step 2: Mixing: Weigh nicardipine hydrochloride and microcrystalline cellulose according to the above mass ratio, put them into a three-dimensional mixer and mix for 30 minutes to make a fine powder of the drug, and take it out for later use;
[0040] Step 3: Preparation of adhesive: Weigh an appropriate amount of hypromellose according to the above mass ratio, add an appropriate amount of hot water to prepare an adhesive with a concentration of 2%, and set aside;
[0041] Step 4: Pill making: put the mixed drug fine powder into the feeding tank of the centrifugal pellet machine, put the adhesive into the liquid supply tank, put the blank pellet core into the pot, turn on the m...
Embodiment 3
[0047] Indications: essential hypertension.
[0048] medicine interactions:
[0049] 1. This product is used together with β-blockers and is well tolerated.
[0050] 2. When this product is used in combination with cimetidine, the plasma concentration of this product will increase.
[0051] 3. When this agent is used in combination with other antihypertensive drugs, there may be an additive effect, and more attention should be paid when using it.
[0052] 4. When this agent is used in combination with digoxin, the blood concentration of digoxin should be measured.
[0053] 5. When this product is used in combination with cyclosporine, the plasma concentration of cyclosporine increases.
[0054] 6. In vitro, therapeutic concentrations of furosemide, propranolol, dipyridamole, warfarin, quinidine, etc. added to human plasma do not change the protein binding rate of this product.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com